Roche Holding AG (RHHBY)
OTCMKTS
· Delayed Price · Currency is USD
41.21
+0.45 (1.10%)
Jul 1, 2025, 3:59 PM EDT
Roche Holding AG Employees
Roche Holding AG had 103,249 employees as of December 31, 2024. The number of employees decreased by 356 or -0.34% compared to the previous year.
Employees
103,249
Change (1Y)
-356
Growth (1Y)
-0.34%
Revenue / Employee
$666,883
Profits / Employee
$88,465
Market Cap
263.69B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 103,249 | -356 | -0.34% |
Dec 31, 2023 | 103,605 | -8 | -0.01% |
Dec 31, 2022 | 103,613 | 2,693 | 2.67% |
Dec 31, 2021 | 100,920 | -545 | -0.54% |
Dec 31, 2020 | 101,465 | 3,730 | 3.82% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
Company Name | Employees |
---|---|
Endo, Inc. | 3,116 |
Elite Pharmaceuticals | 64 |
Tian'an Technology Group | 8 |
Glass House Brands | 374 |
American Oncology Network | 1,914 |
Northwest Biotherapeutics | 25 |
CytoDyn | 9 |
Silence Therapeutics | 116 |
Roche Holding AG News
- 2 days ago - Lomiko Metals Announces Ruisseau Graphite Project Exploration Update, La Roche Zone Extension and Fall Workplan - Business Wire
- 2 days ago - Changes to the Roche Enlarged Corporate Executive Committee - GlobeNewsWire
- 8 days ago - Roche Holding AG (RHHBY) Virtual Hematology Investor Conference Transcript - Seeking Alpha
- 8 days ago - Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars - Benzinga
- 11 days ago - Roche's Genentech reports positive results from lymphoma trial - Seeking Alpha
- 11 days ago - Roche's Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma - GlobeNewsWire
- 11 days ago - Genentech's Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma - Business Wire
- 14 days ago - Roche And Prothena: Why Moving On Makes Sense - Seeking Alpha